Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation.
Zahreddine HA, Culjkovic-Kraljacic B, Assouline S, Gendron P, Romeo AA, Morris SJ, Cormack G, Jaquith JB, Cerchietti L, Cocolakis E, Amri A, Bergeron J, Leber B, Becker MW, Pei S, Jordan CT, Miller WH, Borden KL. Zahreddine HA, et al. Nature. 2014 Jul 3;511(7507):90-3. doi: 10.1038/nature13283. Epub 2014 May 28. Nature. 2014. PMID: 24870236 Free PMC article.
Ribavirin treatment effects on breast cancers overexpressing eIF4E, a biomarker with prognostic specificity for luminal B-type breast cancer.
Pettersson F, Yau C, Dobocan MC, Culjkovic-Kraljacic B, Retrouvey H, Puckett R, Flores LM, Krop IE, Rousseau C, Cocolakis E, Borden KL, Benz CC, Miller WH Jr. Pettersson F, et al. Clin Cancer Res. 2011 May 1;17(9):2874-84. doi: 10.1158/1078-0432.CCR-10-2334. Epub 2011 Mar 17. Clin Cancer Res. 2011. PMID: 21415224 Free PMC article.
Aiding and abetting cancer: mRNA export and the nuclear pore.
Culjkovic-Kraljacic B, Borden KL. Culjkovic-Kraljacic B, et al. Trends Cell Biol. 2013 Jul;23(7):328-35. doi: 10.1016/j.tcb.2013.03.004. Epub 2013 Apr 10. Trends Cell Biol. 2013. PMID: 23582887 Free PMC article. Review.
eIF4E3, a new actor in mRNA metabolism and tumor suppression.
Volpon L, Osborne MJ, Culjkovic-Kraljacic B, Borden KL. Volpon L, et al. Cell Cycle. 2013 Apr 15;12(8):1159-60. doi: 10.4161/cc.24566. Epub 2013 Apr 9. Cell Cycle. 2013. PMID: 23587918 Free PMC article. No abstract available.
A phase I trial of ribavirin and low-dose cytarabine for the treatment of relapsed and refractory acute myeloid leukemia with elevated eIF4E.
Assouline S, Culjkovic-Kraljacic B, Bergeron J, Caplan S, Cocolakis E, Lambert C, Lau CJ, Zahreddine HA, Miller WH Jr, Borden KL. Assouline S, et al. Haematologica. 2015 Jan;100(1):e7-9. doi: 10.3324/haematol.2014.111245. Epub 2014 Nov 25. Haematologica. 2015. PMID: 25425688 Free PMC article. Clinical Trial. No abstract available.
Inducible drug modification: a new form of resistance.
Culjkovic-Kraljacic B, Zahreddine HA, Borden KL. Culjkovic-Kraljacic B, et al. Cell Cycle. 2014;13(16):2485-6. doi: 10.4161/15384101.2014.946372. Cell Cycle. 2014. PMID: 25486186 Free PMC article. No abstract available.
29 results